Skip to main content

Erdafitinib Dosage

Medically reviewed by Drugs.com. Last updated on Feb 13, 2024.

Applies to the following strengths: 3 mg; 4 mg; 5 mg

Usual Adult Dose for Urothelial Carcinoma

8 mg orally once daily; increase to 9 mg orally once daily based on serum phosphate levels and tolerability at 14 to 21 days until disease progression or unacceptable toxicity

Comments


Use: For the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC), that has susceptible FGFR3 or FGFR2 genetic alterations, and progressed during or following at least one line of prior platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.

Renal Dose Adjustments

Mild to moderate renal impairment: No adjustment recommended.
Severe renal impairment: Data not available

Liver Dose Adjustments

Mild to moderate hepatic impairment: No adjustment recommended.
Severe hepatic impairment: Data not available

Dose Adjustments

DOSE REDUCTION SCHEDULE FOR ADVERSE REACTIONS:
9 MG DOSE SCHEDULE:

8 MG DOSE SCHEDULE:

DOSE MODIFICATIONS FOR ADVERSE REACTIONS:
HYPERPHOSPHATEMIA (NOTE: Restrict phosphate intake in all patients to 600 to 800 mg daily; if serum phosphate is above 7 mg/dL consider adding an oral phosphate binder until serum phosphate level returns to less than 5.5 mg/dL):
CENTRAL SEROUS RETINOPATHY/RETINAL PIGMENT EPITHELIAL DETACHMENT (CSR/RPED):
OTHER ADVERSE REACTIONS:

Precautions

CONTRAINDICATIONS:


Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:


Storage requirements:

Patient advice:

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.